News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
800,669 Results
Type
Article (73358)
Company Profile (692)
Press Release (726619)
Section
Business (226208)
Career Advice (3697)
Deals (39112)
Drug Delivery (116)
Drug Development (88730)
Employer Resources (194)
FDA (17679)
Job Trends (17033)
News (385479)
Policy (38534)
Tag
Academia (2974)
Alliances (55492)
Alzheimer's disease (1337)
Approvals (17586)
Artificial intelligence (156)
Bankruptcy (391)
Best Places to Work (12524)
Biotechnology (475)
Breast cancer (131)
Cancer (1181)
Cardiovascular disease (109)
Career advice (3146)
Cell therapy (268)
Clinical research (70119)
Collaboration (420)
Compensation (207)
COVID-19 (2803)
C-suite (106)
Data (1157)
Diabetes (168)
Diagnostics (6680)
Earnings (91508)
Employer resources (167)
Events (125519)
Executive appointments (328)
FDA (18249)
Funding (377)
Gene therapy (202)
GLP-1 (694)
Government (4997)
Healthcare (20704)
Infectious disease (2896)
Inflammatory bowel disease (121)
Interviews (721)
IPO (17505)
Job creations (4939)
Job search strategy (2585)
Layoffs (488)
Legal (9820)
Lung cancer (190)
Manufacturing (200)
Medical device (14402)
Medtech (14407)
Mergers & acquisitions (21662)
Metabolic disorders (472)
Neuroscience (1644)
NextGen Class of 2024 (7617)
Non-profit (5063)
Northern California (1522)
Obesity (271)
Opinion (244)
Patents (112)
People (62750)
Pharmaceutical (137)
Phase I (21611)
Phase II (30599)
Phase III (23088)
Pipeline (470)
Postmarket research (3228)
Preclinical (9544)
Radiopharmaceuticals (258)
Rare diseases (246)
Real estate (7105)
Regulatory (25152)
Research institute (2641)
Resumes & cover letters (578)
Southern California (1345)
Startups (4173)
United States (14581)
Vaccines (653)
Weight loss (221)
Date
Today (1)
Last 7 days (712)
Last 30 days (3641)
Last 365 days (38387)
2024 (35272)
2023 (42565)
2022 (53926)
2021 (58724)
2020 (57668)
2019 (51305)
2018 (39085)
2017 (36799)
2016 (37684)
2015 (43679)
2014 (38274)
2013 (34201)
2012 (36156)
2011 (36232)
2010 (35565)
Location
Africa (1181)
Arizona (203)
Asia (47783)
Australia (8201)
California (3542)
Canada (1315)
China (267)
Colorado (159)
Connecticut (171)
Europe (107644)
Florida (476)
Georgia (127)
Illinois (403)
Indiana (215)
Kansas (102)
Maryland (629)
Massachusetts (2862)
Michigan (178)
Minnesota (298)
New Jersey (1010)
New York (1005)
North Carolina (837)
Northern California (1522)
Ohio (149)
Pennsylvania (871)
South America (1556)
Southern California (1345)
Texas (504)
Washington State (398)
800,669 Results for "hanall biopharma co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
HanAll Biopharma Co., Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.
May 28, 2024
·
7 min read
Drug Development
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).
May 3, 2024
·
7 min read
Business
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2023 and provided business updates.
March 21, 2024
·
10 min read
Press Releases
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
November 4, 2024
·
10 min read
Biotech Bay
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.
May 28, 2024
·
4 min read
Business
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
YS Biopharma Co., Ltd. today issues an official response to the notice of extraordinary meeting of shareholders of YS Biopharma Co., Ltd.
February 12, 2024
·
9 min read
Business
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
HanAll Biopharma achieved 18.4 percent revenue growth in the first quarter compared to the same period last year, recording a revenue of 34.1 billion Korean Won, driven by continued strong sales across key products.
April 30, 2024
·
10 min read
Business
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter and provided business updates.
October 26, 2023
·
10 min read
Business
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s Disease
HanAll Biopharma Co., Ltd. (KRX: 009420.KS) and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620.KS) announced that they have entered into a co-development agreement with NurrOn Pharmaceuticals Inc., a Boston-based preclinical-stage biopharma.
May 25, 2023
·
7 min read
Press Releases
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
July 26, 2024
·
11 min read
1 of 80,067
Next
